Drug profile · INN
sitagliptin
JANUVIA
sitagliptin (JANUVIA) is a dipeptidyl peptidase iv inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: film coated. Current US regulatory status: approved.
Drug details — sitagliptin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- FILM COATED
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
sitagliptin (JANUVIA) is a dipeptidyl peptidase iv inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: film coated. Current US regulatory status: approved.
Key facts
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sitagliptin?
sitagliptin (JANUVIA) is a dipeptidyl peptidase iv inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: film coated. Current US regulatory status: approved.
What is the brand name for sitagliptin?
JANUVIA is a marketed brand name for sitagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sitagliptin?
sitagliptin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.